## Mathias Lichterfeld

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2330123/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. New England Journal of Medicine, 2020, 383, 2291-2293.	27.0	1,069
2	Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. Cell, 2020, 183, 143-157.e13.	28.9	599
3	Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV,the, 2014, 1, e13-e21.	4.7	542
4	T memory stem cells in health and disease. Nature Medicine, 2017, 23, 18-27.	30.7	396
5	HIV-1 persistence in CD4+ T cells with stem cell–like properties. Nature Medicine, 2014, 20, 139-142.	30.7	379
6	Loss of HIV-1–specific CD8+ T Cell Proliferation after Acute HIV-1 Infection and Restoration by Vaccine-induced HIV-1–specific CD4+ T Cells. Journal of Experimental Medicine, 2004, 200, 701-712.	8.5	314
7	Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood, 2005, 106, 3366-3369.	1.4	314
8	HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8+ T Cell Response against HIV-1. PLoS Medicine, 2006, 3, e403.	8.4	273
9	Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells. Journal of Clinical Investigation, 2017, 127, 2689-2696.	8.2	249
10	Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature, 2020, 585, 261-267.	27.8	245
11	Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells. Journal of Virology, 2014, 88, 10056-10065.	3.4	242
12	Selection, Transmission, and Reversion of an Antigen-Processing Cytotoxic T-Lymphocyte Escape Mutation in Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2004, 78, 7069-7078.	3.4	227
13	Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nature Immunology, 2006, 7, 173-178.	14.5	209
14	Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. Journal of Clinical Investigation, 2019, 129, 988-998.	8.2	209
15	Diagnosis of Invasive Septate Mold Infections. American Journal of Clinical Pathology, 2003, 119, 854-858.	0.7	208
16	Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes. PLoS Pathogens, 2014, 10, e1004287.	4.7	179
17	Comprehensive Analysis of Human Immunodeficiency Virus Type 1-Specific CD4 Responses Reveals Marked Immunodominance of gag and nef and the Presence of Broadly Recognized Peptides. Journal of Virology, 2004, 78, 4463-4477.	3.4	171
18	CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. Journal of Clinical Investigation, 2011, 121, 1549-1560.	8.2	156

#	Article	IF	CITATIONS
19	Limited Durability of Viral Control following Treated Acute HIV Infection. PLoS Medicine, 2004, 1, e36.	8.4	149
20	A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes. PLoS Pathogens, 2016, 12, e1005545.	4.7	142
21	Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses. Cell, 2022, 185, 266-282.e15.	28.9	131
22	Increased Natural Killer Cell Activity in Viremic HIV-1 Infection. Journal of Immunology, 2004, 173, 5305-5311.	0.8	128
23	HIV-1–specific cytotoxicity is preferentially mediated by a subset of CD8+ T cells producing both interferon-γ and tumor necrosis factor–α. Blood, 2004, 104, 487-494.	1.4	124
24	Reactivation of latent HIV-1 in central memory CD4+T cells through TLR-1/2 stimulation. Retrovirology, 2013, 10, 119.	2.0	124
25	De Novo Generation of Escape Variant-Specific CD8 + T-Cell Responses following Cytotoxic T-Lymphocyte Escape in Chronic Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2005, 79, 12952-12960.	3.4	122
26	Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2017, 64, 1686-1695.	5.8	122
27	Recognition of a Defined Region within p24 Gag by CD8 + T Cells during Primary Human Immunodeficiency Virus Type 1 Infection in Individuals Expressing Protective HLA Class I Alleles. Journal of Virology, 2007, 81, 7725-7731.	3.4	116
28	Antiretroviral drug toxicity – a challenge for the hepatologist?. Journal of Hepatology, 2002, 36, 283-294.	3.7	115
29	Selective Depletion of High-Avidity Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8 + T Cells after Early HIV-1 Infection. Journal of Virology, 2007, 81, 4199-4214.	3.4	109
30	Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4+ T Cells. Immunity, 2018, 48, 1183-1194.e5.	14.3	109
31	HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. Aids, 2004, 18, 1383-1392.	2.2	99
32	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nature Medicine, 2020, 26, 1339-1350.	30.7	96
33	A viral CTL escape mutation leading to immunoglobulin-like transcript 4–mediated functional inhibition of myelomonocytic cells. Journal of Experimental Medicine, 2007, 204, 2813-2824.	8.5	95
34	HLA-B*35-Px–mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses. Journal of Experimental Medicine, 2009, 206, 2959-2966.	8.5	92
35	Leukocyte Immunoglobulin-Like Receptors Maintain Unique Antigen-Presenting Properties of Circulating Myeloid Dendritic Cells in HIV-1-Infected Elite Controllers. Journal of Virology, 2010, 84, 9463-9471.	3.4	92
36	Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat. Journal of Virology, 2015, 89, 10176-10189.	3.4	89

#	Article	IF	CITATIONS
37	Immunological and Virological Impact of Highly Active Antiretroviral Therapy Initiated during Acute HIVâ€l Infection. Journal of Infectious Diseases, 2006, 194, 734-739.	4.0	86
38	Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy. Journal of Virology, 2015, 89, 11284-11293.	3.4	85
39	LILRB2 Interaction with HLA Class I Correlates with Control of HIV-1 Infection. PLoS Genetics, 2014, 10, e1004196.	3.5	83
40	Diagnosis of Invasive Septate Mold Infections: A Correlation of Microbiological Culture and Histologic or Cytologic Examination. American Journal of Clinical Pathology, 2003, 119, 854-858.	0.7	82
41	Potent Cell-Intrinsic Immune Responses in Dendritic Cells Facilitate HIV-1-Specific T Cell Immunity in HIV-1 Elite Controllers. PLoS Pathogens, 2015, 11, e1004930.	4.7	77
42	Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth. PLoS Pathogens, 2016, 12, e1005472.	4.7	77
43	Mutually Exclusive T-Cell Receptor Induction and Differential Susceptibility to Human Immunodeficiency Virus Type 1 Mutational Escape Associated with a Two-Amino-Acid Difference between HLA Class I Subtypes. Journal of Virology, 2007, 81, 1619-1631.	3.4	75
44	Telomerase activity of HIV-1–specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood, 2008, 112, 3679-3687.	1.4	75
45	Transcriptional Changes during Naturally Acquired Zika Virus Infection Render Dendritic Cells Highly Conducive to Viral Replication. Cell Reports, 2017, 21, 3471-3482.	6.4	74
46	Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile. Science Translational Medicine, 2019, 11, .	12.4	74
47	Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals. PLoS Pathogens, 2018, 14, e1006792.	4.7	74
48	Transcriptional Profiling of CD4 T Cells Identifies Distinct Subgroups of HIV-1 Elite Controllers. Journal of Virology, 2011, 85, 3015-3019.	3.4	69
49	HLA-B63 Presents HLA-B57/B58-Restricted Cytotoxic T-Lymphocyte Epitopes and Is Associated with Low Human Immunodeficiency Virus Load. Journal of Virology, 2005, 79, 10218-10225.	3.4	68
50	HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. Journal of Clinical Investigation, 2018, 128, 4074-4085.	8.2	67
51	Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals. Aids, 2019, 33, 1315-1325.	2.2	66
52	Broad activation of latent HIV-1 in vivo. Nature Communications, 2016, 7, 12731.	12.8	65
53	Hepatitis C Therapy With Interferon-α and Ribavirin Reduces CD4 T-Cell–Associated HIV-1 DNA in HIV-1/Hepatitis C Virus–Coinfected Patients. Journal of Infectious Diseases, 2014, 209, 1315-1320.	4.0	60
54	Dysfunctional HIV-Specific CD8+ T Cell Proliferation Is Associated with Increased Caspase-8 Activity and Mediated by Necroptosis. Immunity, 2014, 41, 1001-1012.	14.3	60

#	Article	IF	CITATIONS
55	Diversity of HIV-1 reservoirs in CD4+ T-cell subpopulations. Current Opinion in HIV and AIDS, 2016, 11, 383-387.	3.8	58
56	Circulating CXCR5+CXCR3+PD-1Io Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth. JCI Insight, 2017, 2, e89574.	5.0	58
57	Treatment of HIV-1-Associated Kaposi's Sarcoma with Pegylated Liposomal Doxorubicin and HAART Simultaneously Induces Effective Tumor Remission and CD4+ T Cell Recovery. Infection, 2005, 33, 140-147.	4.7	55
58	CD4 <sup>+</sup> T-Cell Help Enhances NK Cell Function following Therapeutic HIV-1 Vaccination. Journal of Virology, 2014, 88, 8349-8354.	3.4	52
59	T Memory Stem Cells and HIV: a Long-Term Relationship. Current HIV/AIDS Reports, 2015, 12, 33-40.	3.1	52
60	Signatures of immune selection in intact and defective proviruses distinguish HIV-1 elite controllers. Science Translational Medicine, 2021, 13, eabl4097.	12.4	52
61	HIV-1 DNA sequence diversity and evolution during acute subtype C infection. Nature Communications, 2019, 10, 2737.	12.8	51
62	Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study. PLoS Medicine, 2017, 14, e1002461.	8.4	50
63	Reduced CC Chemokine Receptor (CCR) 1 and CCR5 Surface Expression on Peripheral Blood T Lymphocytes from Patients with Chronic Hepatitis C Infection. Journal of Infectious Diseases, 2002, 185, 1803-1807.	4.0	48
64	Immunodominance of HIV-1-specific CD8+ T-cell responses in acute HIV-1 infection: at the crossroads of viral and host genetics. Trends in Immunology, 2005, 26, 166-171.	6.8	48
65	Soluble HLA-G Inhibits Myeloid Dendritic Cell Function in HIV-1 Infection by Interacting with Leukocyte Immunoglobulin-Like Receptor B2. Journal of Virology, 2010, 84, 10784-10791.	3.4	45
66	Inhibition of HIV-1 Integration in Ex Vivo-Infected CD4 T Cells from Elite Controllers. Journal of Virology, 2011, 85, 9646-9650.	3.4	45
67	Mobilization of CD34+haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4. British Journal of Haematology, 2000, 110, 71-81.	2.5	44
68	A Cell-Intrinsic Inhibitor of HIV-1 Reverse Transcription in CD4+ T Cells from Elite Controllers. Cell Host and Microbe, 2014, 15, 717-728.	11.0	44
69	Prolonged Antiretroviral Therapy Preserves HIV-1-Specific CD8 T Cells with Stem Cell-Like Properties. Journal of Virology, 2015, 89, 7829-7840.	3.4	42
70	Limited Sequence Evolution within Persistently Targeted CD8 Epitopes in Chronic Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2005, 79, 8171-8181.	3.4	41
71	The Majority of Currently Circulating Human Immunodeficiency Virus Type 1 Clade B Viruses Fail To Prime Cytotoxic T-Lymphocyte Responses against an Otherwise Immunodominant HLA-A2-Restricted Epitope: Implications for Vaccine Design. Journal of Virology, 2005, 79, 5000-5005.	3.4	39
72	A Reproducibility-Based Computational Framework Identifies an Inducible, Enhanced Antiviral State in Dendritic Cells from HIV-1 Elite Controllers. Genome Biology, 2018, 19, 10.	8.8	37

#	Article	IF	CITATIONS
73	Dendritic Cell Dysfunction During Primary HIV-1 Infection. Journal of Infectious Diseases, 2011, 204, 1557-1562.	4.0	36
74	A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation. Annals of Internal Medicine, 2022, 175, 95-100.	3.9	36
75	Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19. Clinical Immunology, 2022, 237, 108991.	3.2	36
76	Blunted Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International HIV Controller Collaboration. PLoS ONE, 2014, 9, e85516.	2.5	34
77	The emerging role of leukocyte immunoglobulin-like receptors (LILRs) in HIV-1 infection. Journal of Leukocyte Biology, 2011, 91, 27-33.	3.3	33
78	Elite control of HIV: p21 (waf-1/cip-1) at its best. Cell Cycle, 2012, 11, 4097-4098.	2.6	32
79	Recent progress in understanding HIV reservoirs. Current Opinion in HIV and AIDS, 2018, 13, 137-142.	3.8	31
80	Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients. Aids, 2002, 16, 2083-2085.	2.2	31
81	Pegylated Interferon-α–Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy–Treated HIV-1/Hepatitis C Virus–Coinfected Patients. Clinical Infectious Diseases, 2018, 66, 1910-1917.	5.8	30
82	Metabolic pathway activation distinguishes transcriptional signatures of CD8+ T cells from HIV-1 elite controllers. Aids, 2018, 32, 2669-2677.	2.2	30
83	The tandem-repeat polymorphism of the DC-SIGNR gene does not affect the susceptibility to HIV infection and the progression to AIDSâ~†. Clinical Immunology, 2003, 107, 55-59.	3.2	29
84	Decreased CXCR3 + CD8 T Cells in Advanced Human Immunodeficiency Virus Infection Suggest that a Homing Defect Contributes to Cytotoxic T-Lymphocyte Dysfunction. Journal of Virology, 2007, 81, 8439-8450.	3.4	28
85	CD4 T-cell regeneration in HIV-1 elite controllers. Aids, 2012, 26, 701-706.	2.2	28
86	HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. Clinical Infectious Diseases, 2017, 64, ciw833.	5.8	28
87	Functional Characterization of HLA-G+ Regulatory T Cells in HIV-1 Infection. PLoS Pathogens, 2013, 9, e1003140.	4.7	27
88	Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers. Clinical Infectious Diseases, 2020, 70, 1636-1642.	5.8	27
89	Long noncoding RNA MIR4435-2HG enhances metabolic function of myeloid dendritic cells from HIV-1 elite controllers. Journal of Clinical Investigation, 2021, 131, .	8.2	27
90	High degree of inter-clade cross-reactivity of HIV-1-specific T cell responses at the single peptide level. Aids, 2005, 19, 1449-1456.	2.2	26

#	Article	IF	CITATIONS
91	Blood and Lymph Node Dissemination of Clonal Genome-Intact Human Immunodeficiency Virus 1 DNA Sequences During Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2020, 222, 655-660.	4.0	24
92	Susceptibility to CD8 T-Cell–Mediated Killing Influences the Reservoir of Latently HIV-1–Infected CD4 T Cells. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 1-9.	2.1	23
93	Immunological Fingerprints of Controllers Developing Neutralizing HIV-1 Antibodies. Cell Reports, 2020, 30, 984-996.e4.	6.4	22
94	T cell receptor cross-recognition of an HIV-1 CD8+ T cell epitope presented by closely related alleles from the HLA-A3 superfamily. International Immunology, 2006, 18, 1179-1188.	4.0	20
95	Functional impairment of HIV-specific CD8+ TÂcells precedes aborted spontaneous control of viremia. Immunity, 2021, 54, 2372-2384.e7.	14.3	20
96	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. Cell Reports, 2020, 33, 108502.	6.4	19
97	Random T-Cell Receptor Recruitment in Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8 <sup>+</sup> T Cells from Genetically Identical Twins Infected with the Same HIV-1 Strain. Journal of Virology, 2007, 81, 12666-12669.	3.4	18
98	High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides. International Journal of Antimicrobial Agents, 2010, 35, 96.	2.5	18
99	Systemic inhibition of myeloid dendritic cells by circulating HLA class I molecules in HIV-1 infection. Retrovirology, 2012, 9, 11.	2.0	17
100	Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits <i>Ex Vivo</i> Lipopolysaccharide-Induced Inflammatory Responses. MSphere, 2018, 3, .	2.9	17
101	Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life. Clinical Infectious Diseases, 2021, 72, 388-393.	5.8	17
102	Induction of Strong HIV-1–Specific CD4+ T-Cell Responses Using an HIV-1 gp120/NefTat Vaccine Adjuvanted With AS02A in Antiretroviral-Treated HIV-1–Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 1-9.	2.1	16
103	Differences in the Expressed HLA Class I Alleles Effect the Differential Clustering of HIV Type 1-Specific T Cell Responses in Infected Chinese and Caucasians. AIDS Research and Human Retroviruses, 2004, 20, 557-564.	1.1	14
104	Clinical outcomes of HIV-HCV co-infection in a large cohort of hemophiliac patients. Journal of Infection, 2005, 50, 221-228.	3.3	14
105	Reactivation of latent HIV moves shock-and-kill treatments forward. Nature, 2020, 578, 42-43.	27.8	13
106	Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation. Aids, 2021, 35, 1015-1020.	2.2	13
107	Loss of HIV-1-specific T cell proliferation in chronic HIV-1 infection: cause or consequence of viral replication?. Aids, 2005, 19, 1225-1227.	2.2	12
108	Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 235-241.	2.1	12

#	Article	IF	CITATIONS
109	Viral Reservoir in Early-Treated Human Immunodeficiency Virus-Infected Children and Markers for Sustained Viral Suppression. Clinical Infectious Diseases, 2021, 73, e997-e1003.	5.8	11
110	Follicular T helper cells: hotspots for HIV-1 persistence. Nature Medicine, 2016, 22, 711-712.	30.7	10
111	Preferential susceptibility of Th9 and Th2 CD4+ T cells to X4-tropic HIV-1 infection. Aids, 2017, 31, 2211-2215.	2.2	10
112	HLA-G+ HIV-1-specific CD8 + T cells are associated with HIV-1 immune control. Aids, 2017, 31, 207-212.	2.2	10
113	Rapid Determination of the Δ32 Deletion in the Human CC-Chemokine Receptor 5 (CCR5) Gene without DNA Extraction by LightCycler Real-Time Polymerase Chain Reaction. AIDS Research and Human Retroviruses, 2004, 20, 750-754.	1.1	8
114	Liver histopathology in human immunodeficiency virus-hepatitis C virus co-infected patients with fatal liver disease. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 739-745.	2.8	8
115	Epigenetic regulation of telomerase expression in HIV-1-specific CD8+ T cells. Aids, 2010, 24, 1964-1966.	2.2	8
116	Shelterin Dysfunction and p16 <sup>INK4a</sup> -Mediated Growth Inhibition in HIV-1-Specific CD8 T Cells. Journal of Virology, 2012, 86, 5533-5540.	3.4	7
117	Studies on quantitative phosphopeptide analysis by matrixâ€assisted laser desorption/ionization mass spectrometry without label, chromatography or calibration curves. Rapid Communications in Mass Spectrometry, 2014, 28, 2681-2689.	1.5	7
118	Elite control of HIV: p21 (waf-1/cip-1) at its best. Cell Cycle, 2011, 10, 3213-3214.	2.6	6
119	Immune-profiling of ZIKV-infected patients identifies a distinct function of plasmacytoid dendritic cells for immune cross-regulation. Nature Communications, 2020, 11, 2421.	12.8	6
120	Patterns of pretreatment drug resistance mutations of very early diagnosed and treated infants in Botswana. Aids, 2021, 35, 2413-2421.	2.2	6
121	Mutational Escape in HIV-1 CTL Epitopes Leads to Increased Binding to Inhibitory Myelomonocytic MHC Class I Receptors. PLoS ONE, 2010, 5, e15084.	2.5	5
122	Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo. EClinicalMedicine, 2021, 42, 101225.	7.1	5
123	Treating HIV-1 infection: what might the future hold?. Therapeutic Advances in Chronic Disease, 2011, 2, 293-305.	2.5	4
124	Acute HIV-1 Infection: A Call to Action. Annals of Internal Medicine, 2013, 159, 425.	3.9	3
125	Second European Round Table on the Future Management of HIV. Journal of Virus Eradication, 2015, 1, 211-220.	0.5	3
126	Transcriptional Changes in CD8+ T Cells During Antiretroviral Therapy Intensified With Raltegravir. Open Forum Infectious Diseases, 2015, 2, ofv045.	0.9	2

#	Article	IF	CITATIONS
127	HIV diagnostic algorithm requires confirmatory testing for initial indeterminate or positive screens in the first week of life. Aids, 2020, 34, 1029-1035.	2.2	2
128	Near-Full-Length Single-Genome HIV-1 DNA Sequencing. Methods in Molecular Biology, 2022, 2407, 357-364.	0.9	2
129	Antiretroviral combination therapy markedly reduces risk of heterosexual HIV-1 transmission. Evidence-Based Medicine, 2012, 17, 95-96.	0.6	1
130	Dendritic Cells from HIV-1 Neutralizers Efficiently Induce the Generation of CXCR5+ CXCR3+ PD1Lo CD4 T Cells with B Cell Helper Function. AIDS Research and Human Retroviruses, 2014, 30, A74-A74.	1.1	0
131	D-104 Clonal proliferation of CD4 T cells encoding intact HIV-1. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 40-40.	2.1	0
132	T Memory Stem Cells. , 2014, , 1-6.		0
133	T Memory Stem Cells. , 2018, , 1963-1968.		0
134	Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain. Journal of Virus Eradication, 2015, 1, 211-20.	0.5	0